Vertex Approval Brings Instant Re-evaluation; Small Caps Losing Investors
Executive Summary
The 16% decline by Vertex in April stock trading (minus 4-1/8 for the month) reflects two of the investment formulas depressing the market for the small cap biopharmaceutical companies.